Search tips
Search criteria 


Logo of jlrJournal of Lipid Research
J Lipid Res. 2015 December; 56(12): 2238–2247.
PMCID: PMC4655993

Recent insights into the biological functions of liver fatty acid binding protein 1


Over four decades have passed since liver fatty acid binding protein (FABP)1 was first isolated. There are few protein families for which most of the complete tertiary structures, binding properties, and tissue occurrences are described in such detail and yet new functions are being uncovered for this protein. FABP1 is known to be critical for fatty acid uptake and intracellular transport and also has an important role in regulating lipid metabolism and cellular signaling pathways. FABP1 is an important endogenous cytoprotectant, minimizing hepatocyte oxidative damage and interfering with ischemia-reperfusion and other hepatic injuries. The protein may be targeted for metabolic activation through the cross-talk among many transcriptional factors and their activating ligands. Deficiency or malfunction of FABP1 has been reported in several diseases. FABP1 also influences cell proliferation during liver regeneration and may be considered as a prognostic factor for hepatic surgery. FABP1 binds and modulates the action of many molecules such as fatty acids, heme, and other metalloporphyrins. The ability to bind heme is another cytoprotective property and one that deserves closer investigation. The role of FABP1 in substrate availability and in protection from oxidative stress suggests that FABP1 plays a pivotal role during intracellular bacterial/viral infections by reducing inflammation and the adverse effects of starvation (energy deficiency).

Keywords: fatty liver, heme, infection, inflammation, liver regeneration, metalloporphyrins, nonalcoholic fatty liver disease, oxidative stress, steatosis


Liver fatty acid binding protein (FABP), also known as L-FABP or FABP1 is a 14 kDa soluble protein abundantly found in the cytoplasm of hepatocytes, and to a lesser extent in the nucleus (1, 2) and outer mitochondrial membrane (1, 3). FABP1 is also present in many other tissues, although in less abundance, e.g., enterocytes (4, 5), tubular cells of the kidney, and alveolar epithelium of the lung, among other tissues (6). Species differences exist in the presence or absence of FABP1 in various organs and in its content; e.g., FABP1 is present in human but not mouse kidneys (7, 8). In normal human liver, FABP1 accounts for as much as 7–11% of cytosolic proteins, nearly 2-fold more than in mouse liver (9). Unlike other members in the FABP family, each molecule of FABP1 is capable of binding two molecules of long-chain fatty acids (LCFAs) (Fig. 1) (10). The primary and secondary fatty acid binding sites appear to be interdependent, because both aliphatic chains form favorable hydrophobic interactions. This binding property may directly affect interactions with ligands, enzymes, or membrane systems (11). In addition to binding LCFAs, FABP1 binds fatty acyl-CoAs, peroxisome proliferators, prostaglandins, bile acids, bilirubin, heme, hydroxyl and hydroperoxyl metabolites of fatty acids, lysophosphatidic acids, selenium, and other hydrophobic ligands. Recent work has shown that FABPs may be involved in the transport of endocannabinoids (12, 13) and possibly monoacylglycerols (14). The extensive ligand binding property suggests that FABP1 has multiple functional roles (15). FABP1 can work as a trafficking and delivery controller of various ligands to cellular destinations such as enzymes, membranes, and nucleus. In many respects FABP1 appears to represent the intracellular equivalent to serum albumin, participating in the intracellular storage and transport of fatty acids and their acyl-CoA esters and influencing the metabolic utilization and compartmentalization of LCFAs (16). FABP1 also may be a possible carrier of certain hydrophobic reactants in their passage from cytosol to chromatin (17), and thus may have a direct or indirect effect on cell growth. Moreover, the level of immunostained FABP1 is markedly increased during all stages of mitosis (18, 19), and FABP1 mRNA expression and levels were significantly increased during liver regeneration after 70% hepatectomy in rats. The regeneration activity and hepatic LCFA uptake rates were directly correlated to FABP1 level (20).

Fig. 1.
The crystal structure and ligand binding cavity location of FABP1. Ten antiparallel β-strands (βA to βJ) form a β-barrel. Two oleate ligands (dark gray) are bound in the cavity of FABP1. One oleate is completely buried ...

FABP1 is speculated to have an important cytoprotectant role by binding potentially toxic fatty acids, heme, and other molecules that, when unbound, may cause severe cytotoxicity. FABP1 can, therefore, affect enzyme function by its effect on ligand availability and targeting (21), modulate enzyme activity by changing membrane structure and fluidity (22), and regulate gene expression through activating nuclear receptors (23). PPARs and FABP1 are both found in the nucleus and likely interact directly as part of a signal transduction pathway (23, 24). Thus, FABP1 is likely involved in the signaling pathways for PPARα and PPARγ by transporting their agonists (25). The intracellular concentrations of FABP1 directly correlate with the activities of PPARα and PPARγ, suggesting that FABP1 is a positive regulator of PPAR expression. In the treatment of hypercholesterolemia, statins inhibit cholesterol synthesis and also decrease plasma triglyceride and nonesterified fatty acid levels. FABP1 is upregulated by and involved in the effects of statin treatment on hepatocytes. A molecular mechanism for this induction is suggested by the fact that statins transactivate the PPARα promoter (26). PPARα agonists enhance the transcriptional rate of the FABP1 gene and cause a rise in FABP1 mRNA and protein level (27). The upregulation of FABP1 is significantly correlated with protein content and peroxisomal fatty acid oxidation (28). This finding provides another molecular basis for the hypolipidemic effect of these drugs. The design of drugs affecting gene regulation usually focuses on ligand-activated receptors. However, it should be recalled that cellular chaperones/delivery systems function to transport drugs to their target sites. Therefore, FABP1 and other FABPs could serve as novel therapeutic targets that modulate nuclear receptor activity.

FABP1 concentration in hepatocytes is variable and responsive to changes in physiological and pharmacological conditions. Hepatic levels of FABP1 are gender specific (higher in females than males), increase during pregnancy and lactation (29, 30), decrease with age, and are also regulated by growth hormone (31). The gender influence on FABP1 corresponds to the effects of sex steroid hormones. Testosterone decreases, whereas estrogen increases, FABP1 levels in rats (32). The higher level of FABP1 in female rats, as well as the increased FABP1 content in male animals treated by clofibrate, is not related to differences in the turnover rate of FABP1, but appears to be correlated with an increased content of tissue FABP1 mRNA (33). Starvation and high-fat content diets also have clear and reciprocal effects on FABP1 levels (3436). A high-carbohydrate diet increases FABP1 content in the liver and intestine (37). Low dose chronic alcohol consumption induces a marked increase of FABP1 in the livers of rats (38, 39). Methionine/choline-deficient diets decreased FABP1 significantly in a rat model of nonalcoholic steatohepatitis (NASH) (40), while dexamethasone has been reported to downregulate FABP1 by an indirect endocrine effect (41). Additional details regarding the occurrence distribution, ligand specificity, gene and protein structure, regulation, role in hepatic fatty acid uptake and transportation, and other potential physiological functions of FABP1 have recently been reviewed (4244). Accordingly, the remainder of this review focuses on some new functions of FABP1.


Liver diseases, such as cirrhosis, hepatitis, iron and copper overload, porphyrias, and hepatocellular carcinoma (HCC), are associated with notable changes in cellular lipid metabolic homeostasis, which usually correlate with changes in cellular FABP levels (45). FABP1 may play a regulatory or protective role by: a) controlling availability of LCFAs and their oxidative metabolites, or other ligands such as heme that are potentially cytotoxic (46, 47), thus limiting the free LCFA fraction [In this manner FABP1 serves to protect the cytosol from the otherwise detergent effects of these molecules. Similarly, binding of molecules, such as heme, limits their availability to take part in reactive oxygen species (ROS) production (48)]; b) modulating the interaction of LCFAs or other ligands with nuclear receptors (24); and c) trapping or scavenging ROS (4952).

ROS may result from metabolic processes such as the metabolism of LCFAs, which may lead to the generation of highly reactive oxygen and hydroxyl radicals (53) or those derived from interrupted oxygen metabolism (hypoxia-ischemia/reperfusion). As well, unbound heme becomes highly cytotoxic in the presence of other molecules such as tumor necrosis factor (48). As primary defense mechanisms, binding proteins and antioxidant enzymes in cells such as superoxide dismutase, catalase, and glutathione peroxidase are present to scavenge these reactive species. Prolonged exposure to ROS, however, may deplete the cellular antioxidant capacity and cause cellular oxidative stress (54). FABP1 has been found to contain a cysteine group, which is known to be an effective antioxidant agent participating in S-thiolation/dethiolation reactions (55), and several methionine groups. Methionine residues have nucleophilic sulfur atoms and are regarded as cellular scavengers of activated xenobiotics such as carcinogens (56). Oxidative damage to cellular components may be suppressed by oxidation of the methionines in FABP1 to sulfoxides, which can be reduced back to methionine residues by methionine sulfoxide reductase (57, 58). Methionine sulfoxide reductase is highly expressed in liver (59) and is considered a regulator of cellular antioxidative defense (60, 61). Thus, redox cycling of the FABP1 methionine groups by methionine sulfoxide reductase causes a net scavenging effect by FABP1 for ROS, delineating an important antioxidant defense mechanism in cellular regulation (62) (Fig. 2). The mechanism of FABP1’s antioxidant activity is thought to be through inactivation of the free radicals by FABP1’s methionine and cysteine amino acids (63). FABP1 also binds many lipid peroxidation products (46, 49) and is present at high concentrations (approximately 0.4–0.8 mM) in hepatocytes. For these reasons FABP1 might serve as an endogenous cellular protectant (6466).

Fig. 2.
Cyclic oxidation and reduction of methionine residues scavenge oxidants catalytically. Methionine (Met) is readily oxidized to methionine sulfoxide [Met(O)] by many different forms of ROS, e.g., hydrogen peroxide (H2O2); Met(O) is readily reversed by ...

Antioxidant activity of FABP1 was shown to be greatest when free radicals were released in the hydrophilic domain rather than in the lipophilic domain (63), suggesting that the cell is better protected by FABP1 in the cytosol. Using a hepatoma cell line, Yan et al. (67) reported that a reduction in FABP1 expression using FABP1 siRNA was associated with increased levels of ROS following H2O2-induced oxidative stress. In a rat model of cholestasis in which the common bile duct was ligated, PPAR agonist treatment increased FABP1 expression, and this correlated with a reduction of liver oxidative stress and risk of mortality (68). In a FABP1 gene knockout mouse model, mice exhibited higher sustained hepatic oxidative stress during chronic ethanol ingestion than the control group, suggesting that FABP1 is an antioxidant protein and that its downregulation may be important in the pathogenesis of alcoholic liver disease (69). In a glutathione depletion-induced oxidative stress rat model, upregulation of FABP1, along with upregulation of PPARα-regulated gene transcripts (i.e., acyl-CoA thioesterase-2 and -4), indicated that PPARα activation is involved in hepatocellular protection (70). Wang and colleagues had earlier suggested that FABP1 levels could be targeted through appropriate pharmacological treatment to minimize cellular damage (66, 68). Thus, FABP1 may be a new therapeutic strategy to suppress ROS levels occurring in the liver (71) during chemotherapy (72, 73) or drug-induced liver injury (74, 75).

FABP1 is also constitutively expressed in proximal tubular cells of kidney (76). Renal FABP1 plays a protective role against oxidative stress in kidney and reduces tubulointerstitial and glomerular injury and nephrotoxicity (7, 7779). Expression of human FABP1 in mice (79) significantly reduced the number of macrophages (F4/80) infiltrating the interstitium, the levels of monocyte chemotactic protein-1 and -3, the degree of tubulointerstitial injury, and the deposition of type I collagen in the kidneys of unilaterally ureteral-obstructed mice (lipid peroxidation products were not observed in kidneys within 7 days of unilateral ureteral obstruction).

FABP1 also acts as a heme binding protein, thus limiting its availability in ROS production by shielding its highly reactive Fe-heme group. The regulatory heme pool normally controls cellular heme homeostasis in hepatocytes. A small but critical pool of bound heme regulates expression of 5-aminolevulinate synthase-1, the rate-controlling enzyme for heme synthesis, and heme oxygenase (HMOX), the rate-controlling enzyme for heme breakdown. The size and activity of the regulatory heme pool in hepatocytes may be linked to cytosolic heme-binding proteins. FABP1 has a 10-fold higher affinity for heme than for oleic acid, as well as other organic anions including other (metallo)porphyrins and bilirubin (80, 81). Compared with the binding affinity of human serum albumin for heme, FABP1 has a slightly higher binding affinity with dissociation constants of Kd (FABP1) = 0.15 μM versus Kd (albumin) = 0.5 μM (80, 82). Heme binds at the same binding site as oleate and, thus, acts as an inhibitor for the binding of fatty acids. Ferroheme is a 3-fold stronger competitor of oleate binding than ferriheme; however, the oxidation states of heme do not affect the diffusion of heme in the presence of FABP1 because of its high binding affinity (83). Binding of heme to FABP1 might be an important determinant for drug efficacy by modulating the availability of drugs to their nuclear targets through competitive and allosteric mechanisms. Heme is synthesized in mitochondria and must be translocated to the cytoplasm and endoplasmic reticulum for hemoprotein syntheses (e.g., cytochrome P450s, cytochrome b5, tryptophan pyrrolase, catalase, peroxidase, etc.). This efflux depends on the presence of a cytosolic protein (84). FABP1 likely facilitates heme efflux from mitochondria and cellular translocation (85). However, it is currently unknown whether intracellular FABP1 expression levels affect heme synthesis and metabolism. Whether there are altered levels or activities of FABP1 in hepatic porphyria and whether such levels play a role in modulating symptoms or clinical severity of porphyria are also unknown. Our recent in vitro study found that overexpression of FABP1 in hepatocytes reduces heme-induced cytotoxicity (Wang et al., unpublished observations). HMOX1, the rate-controlling enzyme for heme catabolism, has been found to have cytoprotective and anti-oxidant effects (86). In rats, hepatic glutathione depletion resulted in increased expression of both HMOX1 and FABP1 protein (70), suggesting that FABP1 and HMOX1 may have complementary or synergistic antioxidant effects. It will be very interesting to elucidate the role of FABP1 in heme-mediated cellular oxidative stress and the possible role of FABP1 in modulating the clinical expression of hepatic porphyria.

In summary, there is convincing evidence that FABP1 exerts cytoprotection in liver and kidney and that FABP1 is an effective endogenous antioxidant.


Nonalcoholic fatty liver disease (NAFLD) is the major hepatic manifestation of the metabolic syndrome and is associated with markedly increased risk for development of overt type 2 diabetes mellitus (T2DM), atherosclerotic heart disease, and cardiovascular disease. Approximately 10–20% of NAFLD patients have biochemical and histological evidence of hepatic progressive inflammatory and fibrogenic disorder, often referred to as NASH. Unlike NAFLD, which tends to be a benign condition, NASH patients are at risk for progressing to fibrosis or cirrhosis and developing HCC (87). Although the etiology and pathogenesis of these hepatic manifestations are not well understood, high levels of fatty acids in the liver and the known hepatotoxic effects of these agents raise the possibility that disturbances in hepatic fatty acid binding or oxidation may play a role in the pathogenesis of these conditions.

The importance of FABP1 in regulating a variety of cellular processes (inflammation, immunity, metabolism, and energy homeostasis), together with its role in binding fatty acids, would suggest that inactivation and/or loss of this protein might modulate susceptibility to NAFLD/NASH and perhaps other traits of the metabolic syndrome. Decreased expression of FABP1 not only occurs in rare human genetic lipid malabsorption syndromes such as abetalipoproteinemia and Anderson’s disease (88), but also occurs in more common human metabolic conditions such as NAFLD. FABP1 was overexpressed in simple steatosis patients compared with nonsteatotic patients and was shown to be decreased in NASH patients (89). Expression of FABP1 in NAFLD correlates with an altered expression of its transcription factors, mainly FOXA1 and PPARα (90). Significantly lower FABP1 levels were observed in steatotic rat or mouse models established by administration of methionine choline-deficient diet or 17α-ethynylestradiol (40, 91, 92). Conversely, FABP1 may be involved in a compensatory mechanism to counteract hepatocellular steatosis. Hepatic FABP1 levels are increased nearly 6.9-fold in a sterol carrier protein knockout mouse model of Refsum disease (93). In the liver of streptozotocin-nicotinamide-induced diabetic rats, FABP1 was reduced by ~4.7-fold. Restoration of hepatic FABP1 by receiving a fish oil diet was associated with lowered serum triglycerides and VLDL cholesterol levels and elevated serum high density lipoprotein cholesterol levels, as well as downregulated expression of TNF-α and IL-6, in livers of diabetic rats (94). FABP1 ablation significantly impacted hepatic fatty acid β-oxidative genes mediated by PPARα activation of the dietary n-3 PUFAs (rich fish oil), an even more prominent effect in the context of high glucose (95). Higher dose alcohol consumption is associated with impaired peroxisomal β-oxidation and FABP1 responses to PPARα in rats, and the severity of fatty liver correlated inversely with the level of FABP1. Treatment with clofibrate, a potent PPARα-activating ligand, prevented ethanol-induced oxidative stress, fat accumulation, and inflammatory changes in the liver (96). If these results in rats hold true for humans, targeting FABP1 by dietary therapy or man-made PPARα agonists has a therapeutic value in preventing irregularities in lipid metabolism in T2DM and alcoholic liver disease. The likelihood of NAFLD progression to advanced fibrosis or HCC is also impacted by age, gender, ethnicity, other genetic factors, other risk factors, etc. It is noteworthy to study how FABP1 is involved in this progression in human subjects. Direct parallels between the effects of human variants and observations in FABP1 ablation mice cannot yet be drawn. Uncertainties on the role of FABP1 in the pathology of human obesity and fatty liver include whether FABP1 functions or the extent that it is modulated during the pathogenesis. This underscores the importance of studying FABP1 in human subjects, as well as in murine models of disease.


A common human FABP1 genetic variation at sequence position 94, a threonine to alanine amino acid replacement (T94A), has been identified (97). Carriers of this SNP have higher baseline plasma free fatty acid levels, lower body mass index, and a smaller waist circumference than T94/T94 homozygotes. A significant trend of higher plasma triglyceride (98, 99) and LDL-cholesterol concentrations was also observed (100). This genetic variation alters the protein structure, stability, and interaction with fatty acids as well as PPARα agonists, and subsequently impacts fatty acid metabolism and PPARα activation (99, 101, 102). Therefore, FABP1 T94A missense mutation could influence obesity indices and the risk to exhibit residual hypertriglyceridemia following lipid-lowering therapy. A study of the association of FABP1 SNPs and NAFLD demonstrated that genetic variations within FABP1 impact blood lipoprotein/lipid levels and responses to lipid-lowering therapy with fenofibrate (a cholesterol synthesis inhibitor) and glycogenolysis, which may contribute to a higher risk of NAFLD (98) as well as T2DM and insulin resistance (103). FABP1 polymorphism in a Chinese population was also shown to be associated with increased risk of NAFLD. The study population associated with two SNPs was reported to be at significantly higher risk for developing NAFLD than individuals with one SNP (98). These reports show the influence and importance that FABP1 SNPs have on modulating NAFLD risk.

In order to further understand the importance of FABP1 in cellular processes, FABP1 gene knockout mice have been generated on the C57BL/6 background from two independent laboratories, one referred to as the FABP1−/− mouse (104) and the other as the FABP1−/−-green fluorescent protein (GFP) mouse (105). Both lines of mice exhibit some similar phenotypes with the human FABP1 T94A variants, such as defective hepatic fatty acid uptake, oxidation, VLDL secretion, and triglyceride metabolism (100, 104110). However, results of studies on the roles of FABP1 in obesity and fatty liver in mice fed with different types of high-fat/cholesterol diets have often proven contradictory (Table 1). For example, FABP1−/− mice were observed to gain more body weight and fat tissue mass relative to wild-type mice when fed high-fat/cholesterol diets (110114). This result was reproducible by others using the same line of mice (21). However, in contrast, FABP1−/−-GFP mice fed high-fat diet showed less body weight gain and low risk of hepatic steatosis (115119). Two recent review articles expressed opposing views about whether FABP1 may play an important role in preventing diet-induced obesity and/or steatosis (42, 120). Although dietary exposure, gender, and environmental factors all affect metabolic parameters in mice, design of gene-targeting construct, backcrossing to mouse substrains, and control mice (FABP1+/+ wild-type or FABP1+/+- GFP) in studies may be critical to interpretation of experimental observations. Moreover, GFP has 238 amino acid residues with a 26.9 kDa molecular mass, which is almost double the size of FABP1. Whether such an exogenous GFP replacement of FABP1 in hepatocytes would abundantly alter metabolic phenotypes in mice is not clear. Furthermore, overexpression of GFP in cells has been found to have some biological effects (121, 122) and could specifically affect in vivo nucleic acid metabolism, energy utilization, amino acid catabolism, and immune responses (123, 124). Also, composition of diets, gender, and age of animals all vary between studies. For example, use of a high-fat diet containing hydrogenated coconut oil, containing medium-chain fatty acids that are weakly bound to FABP1 (125), has been reported to be associated with reduced weight gain (126). Moreover, growth and sex steroid hormones regulate FABP1 expression during the entire life span. It is not clear whether ablation of the FABP1 gene affects the hormones that correlate to metabolic phenotypes. There are no systematic data to show what potential compensatory genes are regulated due to ablation of FABP1 and/or in response to high-fat or high-cholesterol diets in these mouse models. In summary, although recent studies of these two FABP1 ablation mouse models do provide new insights to the functions of FABP1, the role of FABP1 in diet-induced obesity and steatosis is divergent. These results highlight the complications in interpretation of genetically altered mouse models. The relevance of results in murine knockout models to humans with metabolic syndromes is uncertain. Thus, direct parallels between the effects of human variants and observations in FABP1 ablation mice cannot yet be drawn. Uncertainties on the role of FABP1 in the pathology of human obesity and fatty liver include whether FABP1 functions or the extent that it is modulated during the pathogenesis. This underscores the importance of studying FABP1 in human subjects, as well as in murine models of disease.

FABP1 gene knockout mouse models and comparison of their phenotypes in response to different diets

Recent studies demonstrate that LCFAs and their metabolites can modulate the action or localization of many transcriptional factors, including PPARs, liver X receptors, and hepatocyte nuclear factor (127). FABP1 has a similar binding spectrum with these proteins and may be targeted for metabolic activation through the cross-talk of these transcriptional factors and the ligands that activate them. A putative cyclic regulation seems to exist for FABP1 gene expression (Fig. 3) in which FABP1 binds a specific ligand, the complex stimulates a transcription factor, which then upregulates FABP1 expression. FABP1 overexpression may reduce ligand availability and slow activation of the transcription factor. Therefore, FABP1 may be either a positive or negative factor in FABP1 expression regulation. FABP1 enhances LCFA uptake and intracellular LCFA transport and targets bound LCFA and/or LCFA-CoA to intracellular organelles’ esterification (endoplasmic reticulum), storage (lipid droplets), secretion (VLDL), or, most importantly, normal biological oxidation (in mitochondria, peroxisomes) (104, 128131). As described above, FABP1 exerts appreciable antioxidant and/or detoxification effects, especially under conditions of increased oxidative stress (66, 68). Loss of FABP1 in liver may render hepatocytes more susceptible to the deleterious effects of LCFA and impact the capacity of hepatic lipid oxidation, thus contributing to the development of inflammation, steatohepatitis, and NAFLD progression. However, overexpression of FABP1 may induce unnecessary hepatic lipid accumulation. Thus, FABP1 likely works as a fine tuner in hepatic lipid metabolism.

Fig. 3.
A partial model of FABP1 in gene and metabolic activation. The ligand is transported through the cytoplasm to the nucleus by FABP1. Upon entering the nucleus, the FABP1:ligand complex binds to the PPAR receptor. The ligand-activated receptor, in turn, ...


The modern sedentary lifestyle of humans today too often is characterized by high caloric intake, low energy expenditure, ingestion of numerous and diverse xenobiotics, and highly stressful work or activities that lead to an unbalanced inflammatory and metabolic homeostasis that results in oxidative stress. Conservation of FABP1 from worms to humans, suggests that FABP1 is of fundamental importance. The roles of FABP1 in energy regulation/production, in protection from oxidative stress, and in binding of heme and other metalloporphyrins suggest that FABP1 plays pivotal roles in resistance to infection and the adverse effects of starvation (energy deficiency) (68, 132, 133). FABP1 has been reported in many metabolic disease processes, such as cholestatic liver disease, cancer, diabetes, obesity, and atherosclerosis. Thus, in view of its highly conserved and central role in lipid metabolism and transport of heme and other ligands, the role of FABP1 in normal and pathological processes is in need of further study. The possible key questions to be answered would include: a) what effects do different levels of FABP1 exert on human diseases such as alcoholic liver disease, NAFLD, NASH, cirrhosis, HCC, and hepatic porphyria; b) should efforts be made to down- or upregulate FABP1 in liver in order to prevent or treat NAFLD; and c) should efforts be made to upregulate FABP1 prior to or post hepatectomy and liver transplant? Answers to these fundamental questions will shape therapeutics for liver diseases.



fatty acid binding protein
green fluorescent protein
hepatocellular carcinoma
heme oxygenase
long-chain fatty acid
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
reactive oxygen species
type 2 diabetes mellitus

This work was supported by Grant HL117199 and co-operative agreements DK065201 and DK083909 from the US National Institutes of Health (to H.L.B.) and by institutional funds from Carolinas HealthCare System.


1. Bordewick U., Heese M., Borchers T., Robenek H., and Spener F. 1989. Compartmentation of hepatic fatty-acid-binding protein in liver cells and its effect on microsomal phosphatidic acid biosynthesis. Biol. Chem. Hoppe Seyler. 370: 229–238. [PubMed]
2. Fahimi H. D., Voelkl A., Vincent S. H., and Muller-Eberhard U. 1990. Localization of the heme-binding protein in the cytoplasm and of a heme-binding protein-like immunoreactive protein in the nucleus of rat liver parenchymal cells: immunocytochemical evidence of the subcellular distribution corroborated by radioimmunoassay and immunoblotting. Hepatology. 11: 859–865. [PubMed]
3. Börchers T., Unterberg C., Rüdel H., Robenek H., and Spener F. 1989. Subcellular distribution of cardiac fatty acid-binding protein in bovine heart muscle and quantitation with an enzyme-linked immunosorbent assay. Biochim. Biophys. Acta. 1002: 54–61. [PubMed]
4. Ho S. Y., and Storch J. 2001. Common mechanisms of monoacylglycerol and fatty acid uptake by human intestinal Caco-2 cells. Am. J. Physiol. Cell Physiol. 281: C1106–C1117. [PubMed]
5. Pelsers M. M., Namiot Z., Kisielewski W., Namiot A., Januszkiewicz M., Hermens W. T., and Glatz J. F. 2003. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem. 36: 529–535. [PubMed]
6. Uhlén M., Fagerberg L., Hallström B. M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson Å., Kampf C., Sjöstedt E., Asplund A., et al. 2015. Proteomics. Tissue-based map of the human proteome. Science. 347: 1260419. [PubMed]
7. Matsui K., Kamijo-Ikemorif A., Sugaya T., Yasuda T., and Kimura K. 2011. Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am. J. Pathol. 178: 1021–1032. [PubMed]
8. Osaki K., Suzuki Y., Sugaya T., Tanifuji C., Nishiyama A., Horikoshi S., and Tomino Y. 2013. Amelioration of angiotensin II-induced salt-sensitive hypertension by liver-type fatty acid-binding protein in proximal tubules. Hypertension. 62: 712–718. [PubMed]
9. Vergani L., Fanin M., Martinuzzi A., Galassi A., Appi A., Carrozzo R., Rosa M., and Angelini C. 1990. Liver fatty acid-binding protein in two cases of human lipid storage. Mol. Cell. Biochem. 98: 225–230. [PubMed]
10. Thompson J., Winter N., Terwey D., Bratt J., and Banaszak L. 1997. The crystal structure of the liver fatty acid-binding protein. A complex with two bound oleates. J. Biol. Chem. 272: 7140–7150. [PubMed]
11. Thompson J., Reese-Wagoner A., and Banaszak L. 1999. Liver fatty acid binding protein: species variation and the accommodation of different ligands. Biochim. Biophys. Acta. 1441: 117–130. [PubMed]
12. Kaczocha M., Rebecchi M. J., Ralph B. P., Teng Y. H., Berger W. T., Galbavy W., Elmes M. W., Glaser S. T., Wang L., Rizzo R. C., et al. 2014. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS One. 9: e94200. [PMC free article] [PubMed]
13. Kaczocha M., Glaser S. T., and Deutsch D. G. 2009. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. USA. 106: 6375–6380. [PubMed]
14. Lagakos W. S., Guan X., Ho S. Y., Sawicki L. R., Corsico B., Kodukula S., Murota K., Stark R. E., and Storch J. 2013. Liver fatty acid-binding protein binds monoacylglycerol in vitro and in mouse liver cytosol. J. Biol. Chem. 288: 19805–19815. [PMC free article] [PubMed]
15. Coe N. R., and Bernlohr D. A. 1998. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta. 1391: 287–306. [PubMed]
16. Bass N. M. 1988. The cellular fatty acid binding proteins: aspects of structure, regulation, and function. Int. Rev. Cytol. 111: 143–184. [PubMed]
17. Wolfrum C., Borchers T., Sacchettini J. C., and Spener F. 2000. Binding of fatty acids and peroxisome proliferators to orthologous fatty acid binding proteins from human, murine, and bovine liver. Biochemistry. 39: 1469–1474. [PubMed]
18. Sorof S., and Custer R. P. 1987. Elevated expression and cell cycle deregulation of a mitosis-associated target polypeptide of a carcinogen in hyperplastic and malignant rat hepatocytes. Cancer Res. 47: 210–220. [PubMed]
19. Custer R. P., and Sorof S. 1985. Mitosis in hepatocytes is generally associated with elevated levels of the target polypeptide of a liver carcinogen. Differentiation. 30: 176–181. [PubMed]
20. Wang G., Chen Q. M., Minuk G. Y., Gong Y., and Burczynski F. J. 2004. Enhanced expression of cytosolic fatty acid binding protein and fatty acid uptake during liver regeneration in rats. Mol. Cell. Biochem. 262: 41–49. [PubMed]
21. Gajda A. M., Zhou Y. X., Agellon L. B., Fried S. K., Kodukula S., Fortson W., Patel K., and Storch J. 2013. Direct comparison of mice null for liver or intestinal fatty acid-binding proteins reveals highly divergent phenotypic responses to high fat feeding. J. Biol. Chem. 288: 30330–30344. [PMC free article] [PubMed]
22. Jefferson J. R., Powell D. M., Rymaszewski Z., Kukowska-Latallo J., Lowe J. B., and Schroeder F. 1990. Altered membrane structure in transfected mouse L-cell fibroblasts expressing rat liver fatty acid-binding protein. J. Biol. Chem. 265: 11062–11068. [PubMed]
23. Lawrence J. W., Kroll D. J., and Eacho P. I. 2000. Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus. J. Lipid Res. 41: 1390–1401. [PubMed]
24. Huang H., Starodub O., McIntosh A., Atshaves B. P., Woldegiorgis G., Kier A. B., and Schroeder F. 2004. Liver fatty acid-binding protein colocalizes with peroxisome proliferator activated receptor alpha and enhances ligand distribution to nuclei of living cells. Biochemistry. 43: 2484–2500. [PubMed]
25. Wolfrum C., Borrmann C. M., Borchers T., and Spener F. 2001. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc. Natl. Acad. Sci. USA. 98: 2323–2328. [PubMed]
26. Landrier J. F., Thomas C., Grober J., Duez H., Percevault F., Souidi M., Linard C., Staels B., and Besnard P. 2004. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J. Biol. Chem. 279: 45512–45518. [PubMed]
27. Nakagawa S., Kawashima Y., Hirose A., and Kozuka H. 1994. Regulation of hepatic level of fatty-acid-binding protein by hormones and clofibric acid in the rat. Biochem. J. 297: 581–584. [PubMed]
28. Kawashima Y., Nakagawa S., Tachibana Y., and Kozuka H. 1983. Effects of peroxisome proliferators on fatty acid-binding protein in rat liver. Biochim. Biophys. Acta. 754: 21–27. [PubMed]
29. Ockner R. K., Burnett D. A., Lysenko N., and Manning J. A. 1979. Sex differences in long chain fatty acid utilization and fatty acid binding protein concentration in rat liver. J. Clin. Invest. 64: 172–181. [PMC free article] [PubMed]
30. Besnard P., Foucaud L., Mallordy A., Berges C., Kaikaus R. M., Bernard A., Bass N. M., and Carlier H. 1995. Expression of fatty acid binding protein in the liver during pregnancy and lactation in the rat. Biochim. Biophys. Acta. 1258: 153–158. [PubMed]
31. Singer S. S., Henkels K., Deucher A., Barker M., Singer J., and Trulzsch D. V. 1996. Growth hormone and aging change rat liver fatty acid binding protein levels. J. Am. Coll. Nutr. 15: 169–174. [PubMed]
32. Ockner R. K., Lysenko N., Manning J. A., Monroe S. E., and Burnett D. A. 1980. Sex steroid modulation of fatty acid utilization and fatty acid binding protein concentration in rat liver. J. Clin. Invest. 65: 1013–1023. [PMC free article] [PubMed]
33. Bass N. M., Manning J. A., Ockner R. K., Gordon J. I., Seetharam S., and Alpers D. H. 1985. Regulation of the biosynthesis of two distinct fatty acid-binding proteins in rat liver and intestine. J. Biol. Chem. 260: 1432–1436. [PubMed]
34. Stein L. B., Mishkin S., Fleischner G., Gatmaitan Z., and Arias I. M. 1976. Effect of fasting on hepatic ligandin, Z protein, and organic anion transfer from plasma in rats. Am. J. Physiol. 231: 1371–1376. [PubMed]
35. Brandes R., and Arad R. 1983. Liver cytosolic fatty acid-binding proteins. Effect of diabetes and starvation. Biochim. Biophys. Acta. 750: 334–339. [PubMed]
36. Paulussen R. J. A., Jansen G. P. M., and Veerkamp J. H. 1986. Fatty acid-binding capacity of cytosolic proteins of various rat tissues: effect of postnatal development, starvation, sex, clofibrate feeding and light cycle. Biochim. Biophys. Acta. 877: 342–349. [PubMed]
37. Haq R. U., and Shrago E. 1985. Dietary and nutritional aspects of fatty acid binding proteins. Chem. Phys. Lipids. 38: 131–135. [PubMed]
38. Pignon J. P., Bailey N. C., Baraona E., and Lieber C. S. 1987. Fatty acid-binding protein: a major contributor to the ethanol-induced increase in liver cytosolic proteins in the rat. Hepatology. 7: 865–871. [PubMed]
39. Shevchuk O., Baraona E., Ma X-L., Pignon J-P., and Lieber C. S. 1991. Gender differences in the response of hepatic fatty acids and cytosolic fatty acid-binding capacity to alcohol consumption in rats. Proc. Soc. Exp. Biol. Med. 198: 584–590. [PubMed]
40. Janevski M., Antonas K. N., Sullivan-Gunn M. J., McGlynn M. A., and Lewandowski P. A. 2011. The effect of cocoa supplementation on hepatic steatosis, reactive oxygen species and LFABP in a rat model of NASH. Comp. Hepatol. 10: 10. [PMC free article] [PubMed]
41. Foucaud L., Niot I., Kanda T., and Besnard P. 1998. Indirect dexamethasone down-regulation of the liver fatty acid-binding protein expression in rat liver. Biochim. Biophys. Acta. 1391: 204–212. [PubMed]
42. Atshaves B. P., Martin G. G., Hostetler H. A., McIntosh A. L., Kier A. B., and Schroeder F. 2010. Liver fatty acid-binding protein and obesity. J. Nutr. Biochem. 21: 1015–1032. [PMC free article] [PubMed]
43. Haunerland N. H., and Spener F. 2004. Fatty acid-binding proteins–insights from genetic manipulations. Prog. Lipid Res. 43: 328–349. [PubMed]
44. Storch J., and Corsico B. 2008. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu. Rev. Nutr. 28: 73–95. [PubMed]
45. Furuhashi M., and Hotamisligil G. S. 2008. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7: 489–503. [PMC free article] [PubMed]
46. Raza H., Pongubala J. R., and Sorof S. 1989. Specific high affinity binding of lipoxygenase metabolites of arachidonic acid by liver fatty acid binding protein. Biochem. Biophys. Res. Commun. 161: 448–455. [PubMed]
47. Atshaves B. P., Storey S. M., Petrescu A., Greenberg C. C., Lyuksyutova O. I., Smith R. 3rd, and Schroeder F. 2002. Expression of fatty acid binding proteins inhibits lipid accumulation and alters toxicity in L cell fibroblasts. Am. J. Physiol. Cell Physiol. 283: C688–C703. [PubMed]
48. Larsen R., Gouveia Z., Soares M. P., and Gozzelino R. 2012. Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front. Pharmacol. 3: 77. [PMC free article] [PubMed]
49. Ek-Von Mentzer B. A., Zhang F., and Hamilton J. A. 2001. Binding of 13-HODE and 15-HETE to phospholipid bilayers, albumin, and intracellular fatty acid binding proteins. J. Biol. Chem. 276: 15575–15580. [PubMed]
50. Ek B. A., Cistola D. P., Hamilton J. A., Kaduce T. L., and Spector A. A. 1997. Fatty acid binding proteins reduce 15-lipoxygenase-induced oxygenation of linoleic acid and arachidonic acid. Biochim. Biophys. Acta. 1346: 75–85. [PubMed]
51. Catala A., Cerruti A., and Arcemis C. 1995. Inhibition of microsomal chemiluminescence by cytosolic fractions containing fatty acid binding protein. Arch. Physiol. Biochem. 103: 39–43. [PubMed]
52. Samanta A., Das D. K., Jones R., George A., and Prasad M. R. 1989. Free radical scavenging by myocardial fatty acid binding protein. Free Radic. Res. Commun. 7: 73–82. [PubMed]
53. Day C. P., and James O. F. 1998. Hepatic steatosis: innocent bystander or guilty party? Hepatology. 27: 1463–1466. [PubMed]
54. Csonka C., Pataki T., Kovacs P., Muller S. L., Schroeter M. L., Tosaki A., and Blasig I. E. 2000. Effects of oxidative stress on the expression of antioxidative defense enzymes in spontaneously hypertensive rat hearts. Free Radic. Biol. Med. 29: 612–619. [PubMed]
55. Thomas J. A., Poland B., and Honzatko R. 1995. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. Arch. Biochem. Biophys. 319: 1–9. [PubMed]
56. Odani S., Namba Y., Ishii A., Ono T., and Fujii H. 2000. Disulfide bonds in rat cutaneous fatty acid-binding protein. J. Biochem. 128: 355–361. [PubMed]
57. Levine R. L., Berlett B. S., Moskovitz J., Mosoni L., and Stadtman E. R. 1999. Methionine residues may protect proteins from critical oxidative damage. Mech. Ageing Dev. 107: 323–332. [PubMed]
58. Moskovitz J., Berlett B. S., Poston J. M., and Stadtman E. R. 1999. Methionine sulfoxide reductase in antioxidant defense. Methods Enzymol. 300: 239–244. [PubMed]
59. Moskovitz J., Jenkins N. A., Gilbert D. J., Copeland N. G., Jursky F., Weissbach H., and Brot N. 1996. Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc. Natl. Acad. Sci. USA. 93: 3205–3208. [PubMed]
60. Stadtman E. R. 2004. Cyclic oxidation and reduction of methionine residues of proteins in antioxidant defense and cellular regulation. Arch. Biochem. Biophys. 423: 2–5. [PubMed]
61. Moskovitz J., Bar-Noy S., Williams W. M., Requena J., Berlett B. S., and Stadtman E. R. 2001. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc. Natl. Acad. Sci. USA. 98: 12920–12925. [PubMed]
62. Stadtman E. R., Moskovitz J., Berlett B. S., and Levine R. L. 2002. Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism. Mol. Cell. Biochem. 234–235: 3–9. [PubMed]
63. Yan J., Gong Y., She Y. M., Wang G., Roberts M. S., and Burczynski F. J. 2009. Molecular mechanism of recombinant liver fatty acid binding protein’s antioxidant activity. J. Lipid Res. 50: 2445–2454. [PMC free article] [PubMed]
64. Sato T., Baba K., Takahashi Y., Uchiumi T., and Odani S. 1996. Rat liver fatty acid-binding protein: identification of a molecular species having a mixed disulfide with cysteine at cysteine-69 and enhanced protease susceptibility. J. Biochem. 120: 908–914. [PubMed]
65. Palacios A., Piergiacomi V. A., and Catala A. 1999. Inhibition of lipid peroxidation of microsomes and mitochondria by cytosolic proteins from rat liver: effect of vitamin A. Int. J. Vitam. Nutr. Res. 69: 61–63. [PubMed]
66. Wang G., Gong Y., Anderson J., Sun D., Minuk G., Roberts M. S., and Burczynski F. J. 2005. Antioxidative function of L-FABP in L-FABP stable transfected Chang liver cells. Hepatology. 42: 871–879. [PubMed]
67. Yan J., Gong Y., Wang G., and Burczynski F. J. 2010. Regulation of liver fatty acid binding protein expression by clofibrate in hepatoma cells. Biochem. Cell Biol. 88: 957–967. [PubMed]
68. Wang G., Shen H., Rajaraman G., Roberts M. S., Gong Y., Jiang P., and Burczynski F. 2007. Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. Eur. J. Pharmacol. 560: 61–68. [PubMed]
69. Smathers R. L., Galligan J. J., Shearn C. T., Fritz K. S., Mercer K., Ronis M., Orlicky D. J., Davidson N. O., and Petersen D. R. 2013. Susceptibility of L-FABP-/- mice to oxidative stress in early-stage alcoholic liver. J. Lipid Res. 54: 1335–1345. [PMC free article] [PubMed]
70. Yamauchi S., Kiyosawa N., Ando Y., Watanabe K., Niino N., Ito K., Yamoto T., Manabe S., and Sanbuissho A. 2011. Hepatic transcriptome and proteome responses against diethyl maleate-induced glutathione depletion in the rat. Arch. Toxicol. 85: 1045–1056. [PubMed]
71. Fong D. G., Nehra V., Lindor K. D., and Buchman A. L. 2000. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology. 32: 3–10. [PubMed]
72. Farrell G. C. 1995. Drug-Induced Liver Diseases. Churchill Livingstone, New York.
73. Lieber C. S., and Abittan C. S. 1999. Pharmacology and metabolism of alcohol, including its metabolic effects and interactions with other drugs. Clin. Dermatol. 17: 365–379. [PubMed]
74. Albano E., Goria-Gatti L., Clot P., Jannone A., and Tomasi A. 1993. Possible role of free radical intermediates in hepatotoxicity of hydrazine derivatives. Toxicol. Ind. Health. 9: 529–538. [PubMed]
75. Gong Y., Wang G., Gong Y., Yan J., Chen Y., and Burczynski F. J. 2014. Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity. BMC Gastroenterol. 14: 44. [PMC free article] [PubMed]
76. Maatman R. G., Van Kuppevelt T. H., and Veerkamp J. H. 1991. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem. J. 273: 759–766. [PubMed]
77. Kanaguchi Y., Suzuki Y., Osaki K., Sugaya T., Horikoshi S., and Tomino Y. 2011. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. Nephrol. Dial. Transplant. 26: 3465–3473. [PMC free article] [PubMed]
78. Ichikawa D., Kamijo-Ikemori A., Sugaya T., Yasuda T., Hoshino S., Igarashi-Migitaka J., Hirata K., and Kimura K. 2012. Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury. Hypertension. 60: 973–980. [PubMed]
79. Kamijo-Ikemori A., Sugaya T., Obama A., Hiroi J., Miura H., Watanabe M., Kumai T., Ohtani-Kaneko R., Hirata K., and Kimura K. 2006. Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am. J. Pathol. 169: 1107–1117. [PubMed]
80. Vincent S. H., and Muller-Eberhard U. 1985. A protein of the Z class of liver cytosolic proteins in the rat that preferentially binds heme. J. Biol. Chem. 260: 14521–14528. [PubMed]
81. Epstein L. F., Bass N. M., Iwahara S., Wilton D. C., and Muller Eberhard U. 1994. Immunological identity of rat liver cytosolic heme-binding protein with purified and recombinant liver fatty acid binding protein by western blots of two-dimensional gels. Biochem. Biophys. Res. Commun. 204: 163–168. [PubMed]
82. Fanali G., Bocedi A., Ascenzi P., and Fasano M. 2007. Modulation of heme and myristate binding to human serum albumin by anti-HIV drugs. An optical and NMR spectroscopic study. FEBS J. 274: 4491–4502. [PubMed]
83. Stewart J. M., Slysz G. W., Pritting M. A., and Muller-Eberhard U. 1996. Ferriheme and ferroheme are isosteric inhibitors of fatty acid binding to rat liver fatty acid binding protein. Biochem. Cell Biol. 74: 249–255. [PubMed]
84. Neuwirt J., Ponka P., and Borova J. 1972. Evidence for the presence of free and protein-bound nonhemoglobin heme in rabbit reticulocytes. Biochim. Biophys. Acta. 264: 235–244. [PubMed]
85. Liem H. H., Grasso J. A., Vincent S. H., and Muller-Eberhard U. 1990. Protein-mediated efflux of heme from isolated rat liver mitochondria. Biochem. Biophys. Res. Commun. 167: 528–534. [PubMed]
86. Vítek L., and Schwertner H. A. 2007. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 43: 1–57. [PubMed]
87. Qian Y., and Fan J. G. 2005. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat. Dis. Int. 4: 173–177. [PubMed]
88. Guilmeau S., Niot I., Laigneau J. P., Devaud H., Petit V., Brousse N., Bouvier R., Ferkdadji L., Besmond C., Aggerbeck L. P., et al. 2007. Decreased expression of Intestinal I- and L-FABP levels in rare human genetic lipid malabsorption syndromes. Histochem. Cell Biol. 128: 115–123. [PubMed]
89. Charlton M., Viker K., Krishnan A., Sanderson S., Veldt B., Kaalsbeek A. J., Kendrick M., Thompson G., Que F., Swain J., et al. 2009. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology. 49: 1375–1384. [PMC free article] [PubMed]
90. Guzmán C., Benet M., Pisonero-Vaquero S., Moya M., Garcia-Mediavilla M. V., Martínez-Chantar M. L., González-Gallego J., Castell J. V., Sánchez-Campos S., and Jover R. 2013. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim. Biophys. Acta. 1831: 803–818. [PubMed]
91. Rinella M. E., Elias M. S., Smolak R. R., Fu T., Borensztajn J., and Green R. M. 2008. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res. 49: 1068–1076. [PMC free article] [PubMed]
92. Hung D. Y., Siebert G. A., Chang P., Burczynski F. J., and Roberts M. S. 2005. Reduced hepatic extraction of palmitate in steatosis correlated to lower level of liver fatty acid binding protein. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G93–G100. [PubMed]
93. Wolfrum C., Ellinghaus P., Fobker M., Seedorf U., Assmann G., Borchers T., and Spener F. 1999. Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J. Lipid Res. 40: 708–714. [PubMed]
94. Devarshi P. P., Jangale N. M., Ghule A. E., Bodhankar S. L., and Harsulkar A. M. 2013. Beneficial effects of flaxseed oil and fish oil diet are through modulation of different hepatic genes involved in lipid metabolism in streptozotocin-nicotinamide induced diabetic rats. Genes Nutr. 8: 329–342. [PMC free article] [PubMed]
95. Petrescu A. D., Huang H., Martin G. G., McIntosh A. L., Storey S. M., Landrock D., Kier A. B., and Schroeder F. 2013. Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARalpha-regulated beta-oxidative enzymes. Am. J. Physiol. Gastrointest. Liver Physiol. 304: G241–G256. [PubMed]
96. Nanji A. A., Dannenberg A. J., Jokelainen K., and Bass N. M. 2004. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J. Pharmacol. Exp. Ther. 310: 417–424. [PubMed]
97. Brouillette C., Bosse Y., Perusse L., Gaudet D., and Vohl M. C. 2004. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J. Hum. Genet. 49: 424–432. [PubMed]
98. Peng X. E., Wu Y. L., Lu Q. Q., Hu Z. J., and Lin X. 2012. Two genetic variants in FABP1 and susceptibility to non-alcohol fatty liver disease in a Chinese population. Gene. 500: 54–58. [PubMed]
99. McIntosh A. L., Huang H., Storey S. M., Landrock K. K., Landrock D., Petrescu A. D., Gupta S., Atshaves B. P., Kier A. B., and Schroeder F. 2014. Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-alpha activation in cultured human female hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 307: G164–G176. [PubMed]
100. Fisher E., Weikert C., Klapper M., Lindner I., Mohlig M., Spranger J., Boeing H., Schrezenmeir J., and Doring F. 2007. L-FABP T94A is associated with fasting triglycerides and LDL-cholesterol in women. Mol. Genet. Metab. 91: 278–284. [PubMed]
101. Martin G. G., McIntosh A. L., Huang H., Gupta S., Atshaves B. P., Landrock K. K., Landrock D., Kier A. B., and Schroeder F. 2013. The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates. Biochemistry. 52: 9347–9357. [PMC free article] [PubMed]
102. Huang H., McIntosh A. L., Martin G. G., Landrock K. K., Landrock D., Gupta S., Atshaves B. P., Kier A. B., and Schroeder F. 2014. Structural and functional interaction of fatty acids with human liver fatty acid-binding protein (L-FABP) T94A variant. FEBS J. 281: 2266–2283. [PMC free article] [PubMed]
103. Mansego M. L., Martinez F., Martinez-Larrad M. T., Zabena C., Rojo G., Morcillo S., Soriguer F., Martin-Escudero J. C., Serrano-Rios M., Redon J., et al. 2012. Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One. 7: e31853. [PMC free article] [PubMed]
104. Martin G. G., Danneberg H., Kumar L. S., Atshaves B. P., Erol E., Bader M., Schroeder F., and Binas B. 2003. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J. Biol. Chem. 278: 21429–21438. [PubMed]
105. Newberry E. P., Xie Y., Kennedy S., Han X., Buhman K. K., Luo J., Gross R. W., and Davidson N. O. 2003. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J. Biol. Chem. 278: 51664–51672. [PubMed]
106. Martin G. G., Atshaves B. P., Huang H., McIntosh A. L., Williams B. J., Pai P. J., Russell D. H., Kier A. B., and Schroeder F. 2009. Hepatic phenotype of liver fatty acid binding protein gene-ablated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G1053–G1065. [PubMed]
107. Erol E., Kumar L. S., Cline G. W., Shulman G. I., Kelly D. P., and Binas B. 2004. Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J. 18: 347–349. [PubMed]
108. Storey S. M., McIntosh A. L., Huang H., Martin G. G., Landrock K. K., Landrock D., Payne H. R., Kier A. B., and Schroeder F. 2012. Loss of intracellular lipid binding proteins differentially impacts saturated fatty acid uptake and nuclear targeting in mouse hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 303: G837–G850. [PubMed]
109. Gao N., Qu X., Yan J., Huang Q., Yuan H. Y., and Ouyang D. S. 2010. L-FABP T94A decreased fatty acid uptake and altered hepatic triglyceride and cholesterol accumulation in Chang liver cells stably transfected with L-FABP. Mol. Cell. Biochem. 345: 207–214. [PubMed]
110. Martin G. G., Atshaves B. P., McIntosh A. L., Payne H. R., Mackie J. T., Kier A. B., and Schroeder F. 2009. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice. Mol. Cell. Biochem. 324: 101–115. [PMC free article] [PubMed]
111. Atshaves B. P., McIntosh A. L., Storey S. M., Landrock K. K., Kier A. B., and Schroeder F. 2010. High dietary fat exacerbates weight gain and obesity in female liver fatty acid binding protein gene-ablated mice. Lipids. 45: 97–110. [PMC free article] [PubMed]
112. McIntosh A. L., Atshaves B. P., Landrock D., Landrock K. K., Martin G. G., Storey S. M., Kier A. B., and Schroeder F. 2013. Liver fatty acid binding protein gene-ablation exacerbates weight gain in high-fat fed female mice. Lipids. 48: 435–448. [PMC free article] [PubMed]
113. Martin G. G., Atshaves B. P., McIntosh A. L., Mackie J. T., Kier A. B., and Schroeder F. 2006. Liver fatty acid binding protein gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G36–G48. [PubMed]
114. Martin G. G., Atshaves B. P., McIntosh A. L., Mackie J. T., Kier A. B., and Schroeder F. 2005. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549–560. [PubMed]
115. Newberry E. P., Xie Y., Kennedy S. M., Luo J., and Davidson N. O. 2006. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology. 44: 1191–1205. [PubMed]
116. Newberry E. P., Kennedy S. M., Xie Y., Luo J., Crooke R. M., Graham M. J., Fu J., Piomelli D., and Davidson N. O. 2012. Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice. J. Lipid Res. 53: 744–754. [PMC free article] [PubMed]
117. Chen A., Tang Y., Davis V., Hsu F. F., Kennedy S. M., Song H., Turk J., Brunt E. M., Newberry E. P., and Davidson N. O. 2013. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology. 57: 2202–2212. [PMC free article] [PubMed]
118. Newberry E. P., Kennedy S. M., Xie Y., Sternard B. T., Luo J., and Davidson N. O. 2008. Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G307–G314. [PubMed]
119. Newberry E. P., Kennedy S. M., Xie Y., Luo J., and Davidson N. O. 2009. Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. Mol. Cell. Biochem. 326: 79–86. [PMC free article] [PubMed]
120. Newberry E. P., and Davidson N. O. 2009. Liver fatty acid binding protein (L-FABP) as a target for the prevention of high fat diet induced obesity and hepatic steatosis. Immunol. Endocr. Metab. Agents Med. Chem. 9: 30–37.
121. Huang W. Y., Aramburu J., Douglas P. S., and Izumo S. 2000. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat. Med. 6: 482–483. [PubMed]
122. Agbulut O., Coirault C., Niederlander N., Huet A., Vicart P., Hagege A., Puceat M., and Menasche P. 2006. GFP expression in muscle cells impairs actin-myosin interactions: implications for cell therapy. Nat. Methods. 3: 331. [PubMed]
123. Stripecke R., Carmen Villacres M., Skelton D., Satake N., Halene S., and Kohn D. 1999. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 6: 1305–1312. [PubMed]
124. Li H., Wei H., Wang Y., Tang H., and Wang Y. 2013. Enhanced green fluorescent protein transgenic expression in vivo is not biologically inert. J. Proteome Res. 12: 3801–3808. [PubMed]
125. Huang H., Starodub O., McIntosh A., Kier A. B., and Schroeder F. 2002. Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells. J. Biol. Chem. 277: 29139–29151. [PubMed]
126. Williams M. A., Tamai K. T., Hincenbergs I., and McIntosh D. J. 1972. Hydrogenated coconut oil and tissue fatty acids in EFA-depleted and EFA-supplemented rats. J. Nutr. 102: 847–855. [PubMed]
127. Georgiadi A., and Kersten S. 2012. Mechanisms of gene regulation by fatty acids. Adv. Nutr. 3: 127–134. [PMC free article] [PubMed]
128. McArthur M. J., Atshaves B. P., Frolov A., Foxworth W. D., Kier A. B., and Schroeder F. 1999. Cellular uptake and intracellular trafficking of long chain fatty acids. J. Lipid Res. 40: 1371–1383. [PubMed]
129. Turnbaugh P. J., Backhed F., Fulton L., and Gordon J. I. 2008. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 3: 213–223. [PMC free article] [PubMed]
130. Atshaves B. P., Storey S. M., Huang H., and Schroeder F. 2004. Liver fatty acid binding protein expression enhances branched-chain fatty acid metabolism. Mol. Cell. Biochem. 259: 115–129. [PubMed]
131. Luxon B. A., and Milliano M. T. 1997. Cytoplasmic codiffusion of fatty acids is not specific for fatty acid binding protein. Am. J. Physiol. 273: C859–C867. [PubMed]
132. Memon R. A., Bass N. M., Moser A. H., Fuller J., Appel R., Grunfeld C., and Feingold K. R. 1999. Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim. Biophys. Acta. 1440: 118–126. [PubMed]
133. Mikolajczak S. A., Jacobs-Lorena V., MacKellar D. C., Camargo N., and Kappe S. H. 2007. L-FABP is a critical host factor for successful malaria liver stage development. Int. J. Parasitol. 37: 483–489. [PubMed]

Articles from Journal of Lipid Research are provided here courtesy of American Society for Biochemistry and Molecular Biology